Dr. Jarell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Northeast Dermatology Associates, PC
155 Borthwick Ave
Portsmouth, NH 03801Phone+1 617-726-5254
Summary
- Dr. Abel Jarell is a dermatologist in Boston, MA. He received his medical degree from Harvard Medical School and has been in practice 19 years. He specializes in dermatopathology and is experienced in dermatopathology.
Education & Training
University of California (San Francisco)Fellowship, Dermatopathology, 2009 - 2010
George Washington UniversityResidency, Neurological Surgery, 2002 - 2003
University of WashingtonResidency, Neurological Surgery, 1999 - 2001- University of Washington School of MedicineInternship, Transitional Year, 1998 - 1999
Harvard Medical SchoolClass of 1998
Certifications & Licensure
CA State Medical License 2009 - Present
MA State Medical License 2008 - 2026
MD State Medical License 2012 - 2026
ME State Medical License 2018 - 2025
NH State Medical License 2011 - 2025
DC State Medical License 2002 - 2016
NY State Medical License 2014 - 2016- American Board of Dermatology Dermatology
- American Board of Dermatology Dermatopathology
- Join now to see all
Publications & Presentations
PubMed
- Safety and tolerability of tirbanibulin ointment 1% treatment on 100 cmof the face or scalp in patients with actinic keratosis: A phase 3 study.Neal Bhatia, Edward Lain, Abel Jarell, Janet DuBois, Maria Luisa Tamarit
JAAD International. 2024-12-01 - 1 citationsThe Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis.Jennifer Soung, Vivian Laquer, Joseph F Merola, Angela Moore, Hany Elmaraghy
Dermatology and Therapy. 2024-08-01 - A clinical impact study of dermatologists' use of diagnostic gene expression profile testing to guide patient management.Alexander Witkowski, Abel D Jarell, Kelli L Ahmed, Jennifer J Siegel, Brooke H Russell
Melanoma Management. 2024-01-01
Press Mentions
Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests Through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual MeetingOctober 10th, 2022- Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous MelanomaSeptember 23rd, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
